Clinical Trial Detail

NCT ID NCT03010358
Title Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications

follicular lymphoma

CLL/SLL

chronic lymphocytic leukemia

prolymphocytic leukemia

hairy cell leukemia

marginal zone B-cell lymphoma

lymphoplasmacytic lymphoma

mantle cell lymphoma

Therapies

Entospletinib + Obinutuzumab

Age Groups: adult senior

No variant requirements are available.